SHANDONG BOAN BIOTECHNOLOGY CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 HKD | +0.40% |
|
-2.52% | -35.10% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 722M 100M 782M 8.35B | Sales 2025 * | 930M 129M 1.01B 10.75B | Capitalization | 4.72B 653M 5.1B 54.49B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 7.21 x |
| Net Debt 2024 * | 494M 68.37M 534M 5.71B | Net Debt 2025 * | 639M 88.39M 691M 7.38B | EV / Sales 2025 * | 5.76 x |
| P/E ratio 2024 * |
-25.5
x | P/E ratio 2025 * |
-33
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 19.84% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.40% | ||
| 1 week | -2.52% | ||
| Current month | -5.09% | ||
| 1 month | -12.67% | ||
| 3 months | -10.18% | ||
| 6 months | -32.39% | ||
| Current year | -35.10% |
1 week
9.88
10.96
1 month
9.7211.30
Current year
9.2916.00
1 year
9.2924.20
3 years
9.2940.00
5 years
9.2940.00
10 years
9.2940.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jiang Hua
CEO | Chief Executive Officer | 46 | 22/20/22 |
Shenghan Wang
DFI | Director of Finance/CFO | 44 | 01/20/01 |
Chang Lin Dou
CTO | Chief Tech/Sci/R&D Officer | 61 | 14/17/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuan Chong Liu
BRD | Director/Board Member | 60 | 22/20/22 |
Lu Wen Shi
BRD | Director/Board Member | 60 | 23/21/23 |
Ji Xiong Dai
BRD | Director/Board Member | 65 | 23/21/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 10.06 | +0.40% | 206 600 |
| 08/24/08 | 10.02 | -0.20% | 213,600 |
| 07/24/07 | 10.04 | -0.59% | 196,400 |
| 06/24/06 | 10.1 | -1.37% | 236,000 |
| 03/24/03 | 10.24 | -0.78% | 123,200 |
Delayed Quote Hong Kong S.E., May 09, 2024 at 01:38 pm IST
More quotes
Shandong Boan Biotechnology Co Ltd is a China-based company primarily engaged in biopharmaceuticals. The Company is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The Company has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The Company operates mainly in the domestic Chinese market and overseas markets.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
9.263
CNY
Average target price
10.44
CNY
Spread / Average Target
+12.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.10% | 653M | |
| -3.35% | 88.91B | |
| +4.08% | 41.25B | |
| -15.09% | 31.99B | |
| +51.08% | 24.73B | |
| -15.13% | 15.54B | |
| -40.39% | 12.07B | |
| -8.63% | 12.05B | |
| -14.78% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- 6955 Stock